The conference drew record attendance, with an unofficial total of 1,902.
The company acquired the technology in February for an undisclosed amount.
Industry veteran said he will consolidate the firm’s ophthalmic business efforts under one strategy.
The dry eye treatment’s net revenues jumped 20 percent year over year.
A spokesman for the company confirmed that the list price of Xiidra for a 30-day supply is $426.73.
The deal calls for $95 million up front, plus a milestone payment.
Products featured in the exhibit hall included the TrueVision 3D heads-up display at Alcon’s booth and new surgical instruments shown by Bausch + Lomb.
Study found that patients were affected differently based on their genotype.
The Argus II makes it possible to see squares, moving lines, and alternating bands of light and dark.
Patient selection makes a difference in the efficacy of the treatment in VMA, Mathew MacCumber said.
The half-day forum featured 44 speakers, with presentations by 16 companies.
In late July, Prof. Dr. S. Natarajan of India performed 41 surgeries in two and a half days.
Biennial joint conference will be held in mid-September in Copenhagen, Denmark.
The segment is expected to grow at a compounded rate of nearly 27 percent over the next five years.
The segment is expected to grow at a rate of 5.4 percent over the next five years as new products are commercialized.
The segment is expected to grow 6 to 8 percent through 2018.
The firm marked two milestones, receiving CE marking in Europe for its Dailies Total1 Multifocal and PanOptix trifocal IOL with UltraSert.
While interim results were presented at the 2014 AAO meeting, the latest results looked at three-year follow-up.
The company is the third to begin commercialization of a retinal implant-based artificial vision system.
You are not currently logged in.
©2017 Market Scope
Lost your Password